Details for New Drug Application (NDA): 218159
✉ Email this page to a colleague
NDA 218159 describes TRAVOPROST, which is a drug marketed by Alembic, Apotex, Chartwell Rx, Gland Pharma Ltd, Lupin Ltd, Micro Labs, Mylan, and Somerset Theraps Llc, and is included in eight NDAs. It is available from nine suppliers. Additional details are available on the TRAVOPROST profile page.
The generic ingredient in TRAVOPROST is travoprost. There are fifteen drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the travoprost profile page.
The generic ingredient in TRAVOPROST is travoprost. There are fifteen drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the travoprost profile page.
Summary for 218159
| Tradename: | TRAVOPROST |
| Applicant: | Gland Pharma Ltd |
| Ingredient: | travoprost |
| Patents: | 0 |
Suppliers and Packaging for NDA: 218159
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| TRAVOPROST | travoprost | SOLUTION/DROPS;OPHTHALMIC | 218159 | ANDA | Gland Pharma Limited | 68083-601 | 68083-601-01 | 1 BOTTLE in 1 CARTON (68083-601-01) / 2.5 mL in 1 BOTTLE |
| TRAVOPROST | travoprost | SOLUTION/DROPS;OPHTHALMIC | 218159 | ANDA | Gland Pharma Limited | 68083-602 | 68083-602-01 | 1 BOTTLE in 1 CARTON (68083-602-01) / 5 mL in 1 BOTTLE |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION/DROPS;OPHTHALMIC | Strength | 0.004% | ||||
| Approval Date: | Jul 12, 2024 | TE: | AT | RLD: | No | ||||
Complete Access Available with Subscription
